Ascend announces its portfolio company Aiforia Technologies public listing
Helsinki, Finland - Ascend Capital Partners announces Aiforia Technologies (NASDAQ: AIFORIA) has begun training on Nasdaq First North Growth Market Finland today.
The company belongs to Health care sector. Aiforia Technologies is the 197th company to be admitted to trading on Nasdaq’s Nordic markets* in 2021, and it represents the 29th listing on Nasdaq Helsinki in 2021.
Jukka Tapaninen, CEO of Aiforia Technologies, comments: “We are elated with the interest and trust shown by investors in Aiforia. Pathologists are pivotal to the healthcare system, investigating and diagnosing patient samples to guide medical treatment. AI is able to bring precision and efficiency to evaluating medical images, beyond that of current capabilities. The funds raised in the IPO will support the planned implementation of Aiforia's growth strategy as well as in taking new steps towards our mission to provide the highest quality solutions for AI-assisted image analysis in pathology to enable personalised and democratised care for patients. I warmly welcome our new shareholders!"
“We are proud to welcome Aiforia Technologies to Nasdaq First North Growth Market,“ says Henrik Husman, President of Nasdaq Helsinki. “The artificial intelligence software developed for medical needs by the company can help patients get faster and better treatment, and it has an important role for patients’ well-being. Aiforia Technologies is a great addition to our Health care sector.”
Aiforia’s Nasdaq listing follows after closing its €17.5M Series B funding round in September 2021. The funding round was led by Epredia's UK entity, a subsidiary of PHC Holdings Corporation. The funding was used to develop and commercialize Aiforia’s portfolio of clinical tools for AI-assisted support in the diagnosis of some of the world’s most prevalent diseases like breast and lung cancer, which received CE-IVD clinical marking.
About Aiforia Technologies
Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis beyond current capabilities, across a variety of fields from oncology to neuroscience and more. Our mission is to provide high-quality AI solutions for image-based diagnostics, enabling personalized and better care for patients. Find out more: www.aiforia.com
About Nasdaq First North Growth Market
Nasdaq First North Growth Market is a registered SME growth market, as defined by the Directive on Markets in Financial Instruments (EU 2014/65). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North Growth Market and not the legal requirements for admission to trading on a regulated market, such as the Nasdaq Nordic Main Market. The risk in such an investment may be higher than on the main market.
The Premier segment within Nasdaq First North Growth Market is designed to further assist companies in raising investor visibility and to prepare them for a Main Market listing. The Premier segment targets companies that make a conscious decision to comply with higher disclosure and accounting standards than imposed under the Nasdaq First North Growth Market rules.
About Epredia
Epredia is a global leader in the anatomical pathology field, providing comprehensive solutions for precision cancer diagnostics and tissue diagnostics. Powered by key brands, including Erie Scientific, Menzel-Gläser, Microm, Shandon, and Richard-Allan Scientific, Epredia’s portfolio includes microscope slides, instruments and consumables. Epredia was established following the acquisition of Thermo Fisher Scientific’s Anatomical Pathology business by PHC Holdings in 2019. Epredia has major sites in the United States, the United Kingdom, Germany, Switzerland and China with a total of around 1,200 employees. Epredia is committed to achieving its mission to improve lives by enhancing cancer diagnostics for patients around the world. For further information on Epredia and its products, please visit www.epredia.com.
Find the original article here: https://view.news.eu.nasdaq.com/view?id=b3466d42b901b928880e9ebe240b853af&lang=en